Novo Nordisk shares fall further as new CEO faces US challenges

Novo Nordisk shares continued to decline, falling an additional 3.1% on Wednesday after Tuesday's 23% drop that erased $70 billion in market value, following a profit warning and a significant cut to its 2025 sales growth outlook. The revised forecast is primarily attributed to intense competition from compounded Wegovy copycats in the U.S., which surprised investors. The appointment of new CEO Maziar Mike Doustdar and management's perceived failure to reassure the market have led to a "credibility issue," prompting Barclays to downgrade the stock and JPMorgan to cut its price target, as the company now engages the FDA to combat unlawful compounding.

Analysis

Novo Nordisk is facing a significant crisis of confidence, evidenced by a share price collapse that erased $70 billion in market value following a profit warning. The primary driver for this downturn is a severe and unexpected challenge from compounded, or 'copycat', versions of its key obesity drug, Wegovy, in the U.S. market, which forced the company to slash its 2025 sales growth outlook. This development has not only damaged the company's financial forecasts but has also created what Barclays terms a "severe credibility issue," as management's public commentary, including the new CEO's statement about "fantastic growth," appears disconnected from the market's perception of the threat. The market's reaction is underscored by specific analyst actions: Barclays downgraded the stock to "equal-weight," and while JPMorgan maintained an "overweight" rating, it sharply cut its price target from 650 to 500 crowns. The company's attempts to regain control by engaging the U.S. FDA are noted, but investor sentiment remains extremely negative pending tangible evidence of execution against its newly lowered targets.

Key Decisions for Investors

• Investors should reassess their exposure to Novo Nordisk, as the surprise intensity of U.S. competition and the resulting management credibility gap introduce significant new risks to the investment thesis.
• Monitor U.S. prescription data for Wegovy and any FDA announcements on compounded drugs, as these are now the key near-term catalysts that will validate or invalidate the company's new, lower guidance.
• Given the stock's severe technical breakdown and cautious analyst revisions, initiating new long positions is high-risk until there is clear evidence that the company can stabilize its market share and execute against its revised targets.